Confirmatory evidence was obtained by showing similar effects when applying two selective M1R agonists to three different colon cancer cell lines, and attenuation of these effects when we pre-incubated cells with a selective inhibitor of M1R activation. The gene discussed is CHRM1; the disease is colonic neoplasm.